Mink Therapeutics Investor Relations Material
Latest events
Q1 2025
Mink Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Mink Therapeutics Inc
Access all reports
Mink Therapeutics Inc. is a biotechnology company that focuses on developing immunotherapy treatments. The company specializes in creating allogeneic, off-the-shelf therapies derived from invariant natural killer T (iNKT) cells. These therapies are designed to target cancer and other immune-related diseases. Mink Therapeutics’ approach aims to harness the natural immune response, offering potential treatments that enhance the body’s ability to fight diseases. The company is headquartered in New York, United States, and its shares are listed on the NASDAQ.
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
INKT
Country
🇺🇸 United States